Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells

Experimental Hematology

Volumn 34, Issue 12, 2006, Pages 1655-1662

  Blum, Ariane ^a   Chaperot, Laurence ^a   Molens, Jean Paul ^a   Foissaud, Vincent ^b   Plantaz, Dominique ^c   Plumas, Joël ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b PERCY MILITARY HOSPITAL   (France)

^c HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL ISOLATION; CELL KILLING; CELL LINE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; LEUKEMIA CELL; NATURAL KILLER T CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING;

APOPTOSIS; BINDING SITES; CASPASES; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, PLASMA CELL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SENSITIVITY AND SPECIFICITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33751513545     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.08.002     Document Type: Article

References (41)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
2. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., and Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185 (1997) 1101-1111
3. Dzionek A., Fuchs A., Schmidt P., et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000) 6037-6046
4. Chaperot L., Bendriss N., Manches O., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97 (2001) 3210-3217
5. Chaperot L., Perrot I., Jacob M.C., et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 34 (2004) 418-426
6. Bendriss-Vermare N., Chaperot L., Peoc'h M., et al. In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia 18 (2004) 1491-1498
7. Briere F., Bendriss-Vermare N., Delale T., et al. Origin and filiation of human plasmacytoid dendritic cells. Hum Immunol 63 (2002) 1081-1093
8. + lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 88 (2003) 941-955
9. + malignancies. Blood 99 (2002) 1556-1563
10. Garber K. New apoptosis drugs face critical test. Nat Biotechnol 23 (2005) 409-411
11. Jeremias I., and Debatin K.M. TRAIL induces apoptosis and activation of NFκB. Eur Cytokine Netw 9 (1998) 687-688
12. Screaton G., and Xu X.N. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol 12 (2000) 316-322
13. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
14. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
15. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10 (2003) 66-75
16. Pukac L., Kanakaraj P., Humphreys R., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92 (2005) 1430-1441
17. Georgakis G.V., Li Y., Humphreys R., et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130 (2005) 501-510
18. Chaperot L., Blum A., Manches O., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176 (2006) 248-255
19. Jacob M.C., Agrawal S., Chaperot L., et al. Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. Leukemia 13 (1999) 1428-1433
20. Plumas J., Chaperot L., Jacob M.C., et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 25 (1995) 3332-3341
21. Plasilova M., Zivny J., Jelinek J., et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16 (2002) 67-73
22. Sato K., Hida S., Takayanagi H., et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur J Immunol 31 (2001) 3138-3146
23. Johnsen A.C., Haux J., Steinkjer B., et al. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 11 (1999) 664-672
24. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14 (2003) 337-348
25. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
26. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20 (2002) 621-667
27. Langenkamp A., Messi M., Lanzavecchia A., and Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1 (2000) 311-316
28. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194 (2001) 863-869
29. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 (2004) 1219-1226
30. + T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 101 (2003) 3520-3526
31. + cytotoxic T lymphocytes by dendritic cells. J Exp Med 166 (1987) 182-194
32. Pileri S.A., Grogan T.M., Harris N.L., et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41 (2002) 1-29
33. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
34. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
35. Riccioni R., Pasquini L., Mariani G., et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90 (2005) 612-624
36. Sprick M.R., Weigand M.A., Rieser E., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
37. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 139 (2003) 89-97
38. Wang J., Zheng L., Lobito A., et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98 (1999) 47-58
39. Bodmer J.L., Holler N., Reynard S., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2 (2000) 241-243
40. Suliman A., Lam A., Datta R., and Srivastava R.K. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20 (2001) 2122-2133
41. Barnhart B.C., Alappat E.C., and Peter M.E. The CD95 type I/type II model. Semin Immunol 15 (2003) 185-193